Navigation Links
MGC Diagnostics Corporation Announces Partnership with Frontera Strategies, LP
Date:2/27/2013

SAINT PAUL, Minn., Feb. 27, 2013 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology company, today announced it has entered into a partnership with Frontera Strategies, LP ("Frontera"), the leading provider of in-office cardiac, pulmonary, vascular and neurological testing services. As a result of this partnership, Frontera has agreed to purchase new cardiopulmonary diagnostic equipment with customized systems developed and designed by MGC Diagnostics to better meet the demanding requirements of Frontera's mobile testing procedures. Based in Irving, Texas, Frontera Strategies has been recognized by Modern Healthcare as one of the "Best Places to Work" in the healthcare industry.

(Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

MGC Diagnostics, ranked 'Best-In-Class' by MD Buyline's User Satisfaction Report, is focused on providing non-invasive diagnostic systems with unmatched service and support throughout the U.S. and internationally.

Kai Pinkerton , Clinical Operations Manager of Frontera, commented "We chose MGC Diagnostics because of their product quality, service excellence and attractive company culture. Clinically we were pleased with the products and MGC Diagnostics was flexible enough to work out a winning solution for us. At Frontera the experience for our patients and customers is our number one priority. Partnering with MGC Diagnostics, who leads their industry in service excellence, was a natural fit."

Richard Baker , Co-founder and Partner of Frontera, added "As a leader in mobile diagnostic services, we are excited to partner with MGC Diagnostics to better serve our customers and their patients within the Oklahoma and Texas markets. Our goal is to be a thought leader in driving down healthcare costs and we are looking for ways to bring better, more cost efficient diagnostic testing to the marketplace."

Gregg O. Lehman , Ph.D., Chief Executive Officer and President of MGC Diagnostics, commented "We are pleased to have been chosen by Frontera to assist them in maintaining a leadership role in mobile testing. As part of our efforts to improve patient outcomes and reduce healthcare costs, we remain committed to providing innovative diagnostic equipment to mobile testing services focused at physicians' offices, as well as at traditional healthcare facilities."

About Frontera Strategies
Frontera is the leading provider of in-office cardiac, pulmonary, vascular and neurological testing services. With more than 2,000 partners across Texas and Oklahoma, Frontera serves physicians in Dallas, Ft. Worth, Austin, Houston, San Antonio, Lubbock, Amarillo, Oklahoma City and Tulsa.  Frontera was founded in 2001 by partners Richard Baker , Nate Nelson and Ches Williams .  For more information, please visit: http://www.teamfrontera.com.

About MGC Diagnostics
MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation), is a global medical technology company dedicated to cardiorespiratory health solutions. MGC Diagnostics develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking Statements
From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward−looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forward−looking statements, the Company claims the protection of the safe harbor for forward−looking statements contained in federal securities laws. These forward−looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward−looking statements. For a list of these factors¸ see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2012, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.Contact:Gregg O. Lehman, Ph.D.Joe Dorame, Robert Blum, Joe DiazMGC Diagnostics CorporationLytham Partners, LLCChief Executive Officer(602) 889-9700(651) 484-4874mgcd@lythampartners.com


'/>"/>
SOURCE MGC Diagnostics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. QBC Diagnostics Awarded GSA Contract
2. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
3. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
4. Ariosa Diagnostics to Present and Exhibit at the 16th International Conference on Prenatal Diagnosis and Therapy
5. ZINO Society Targets Medical Devices, Healthcare IT and Diagnostics
6. Quest Diagnostics To Speak At The Wells Fargo Securities 2012 Healthcare Conference
7. Breakthrough Prostate Cancer Diagnostics
8. NicOx Signs Worldwide Licensing Agreement With Rapid Pathogen Screening, Inc. For Ophthalmic Diagnostics
9. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
10. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
11. Quest Diagnostics to Release Second Quarter 2012 Financial Results on July 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):